HPSE2

heparanase 2 (inactive), the group of MicroRNA protein coding host genes|Heparanases

Basic information

Region (hg38): 10:98457077-99235862

Previous symbols: [ "UFS" ]

Links

ENSG00000172987NCBI:60495OMIM:613469HGNC:18374Uniprot:Q8WWQ2AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • urofacial syndrome type 1 (Definitive), mode of inheritance: AR
  • urofacial syndrome type 1 (Moderate), mode of inheritance: AR
  • Ochoa syndrome (Supportive), mode of inheritance: AR
  • urofacial syndrome type 1 (Strong), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Ochoa syndrome; Urofacial syndrome 1ARRenalIndividuals are at high risk of infantile-onset vesicoureteral reflux leading to kidney damage, hypertension, and eventual renal failure, and surveillance and preventive measures related to manifestations such as urinary tract/renal infections may be beneficialCraniofacial; Neurologic; Renal11446407; 19839856; 19669792; 20560209; 20560210; 20605127; 21332471; 21450525

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the HPSE2 gene.

  • Urofacial_syndrome_type_1 (99 variants)
  • not_provided (89 variants)
  • Inborn_genetic_diseases (76 variants)
  • HPSE2-related_disorder (11 variants)
  • Ochoa_syndrome (3 variants)
  • Congenital_anomaly_of_kidney_and_urinary_tract (2 variants)
  • not_specified (2 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the HPSE2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000021828.5. Only rare variants are included in the table.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
3
clinvar
25
clinvar
1
clinvar
29
missense
1
clinvar
137
clinvar
5
clinvar
1
clinvar
144
nonsense
3
clinvar
2
clinvar
1
clinvar
6
start loss
0
frameshift
3
clinvar
6
clinvar
9
splice donor/acceptor (+/-2bp)
2
clinvar
4
clinvar
6
Total 9 12 141 30 2

Highest pathogenic variant AF is 0.000419418

Loading clinvar variants...

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
HPSE2protein_codingprotein_codingENST00000370552 12776745
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.0001510.9981256700781257480.000310
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.2453163290.9620.00001893822
Missense in Polyphen122135.080.903191580
Synonymous-0.8141441321.090.000006771224
Loss of Function2.791126.50.4150.00000136327

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0005790.000579
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.00009450.0000924
European (Non-Finnish)0.0005200.000519
Middle Eastern0.00005440.0000544
South Asian0.00006540.0000653
Other0.0004900.000489

dbNSFP

Source: dbNSFP

Function
FUNCTION: Binds heparin and heparan sulfate with high affinity, but lacks heparanase activity. Inhibits HPSE, possibly by competing for its substrates (in vitro). {ECO:0000269|PubMed:20576607}.;
Disease
DISEASE: Urofacial syndrome 1 (UFS1) [MIM:236730]: A rare autosomal recessive disorder characterized by facial grimacing when attempting to smile and failure of the urinary bladder to void completely despite a lack of anatomical bladder outflow obstruction or overt neurological damage. Affected individuals often have reflux of infected urine from the bladder to the upper renal tract, with a risk of kidney damage and renal failure. {ECO:0000269|PubMed:20560209, ECO:0000269|PubMed:20560210}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Proteoglycans in cancer - Homo sapiens (human);Glycosaminoglycan degradation - Homo sapiens (human);Metabolism of carbohydrates;HS-GAG degradation;Heparan sulfate/heparin (HS-GAG) metabolism;Glycosaminoglycan metabolism;Metabolism (Consensus)

Recessive Scores

pRec
0.185

Intolerance Scores

loftool
0.898
rvis_EVS
0.09
rvis_percentile_EVS
60.57

Haploinsufficiency Scores

pHI
0.297
hipred
N
hipred_score
0.454
ghis
0.455

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
N
gene_indispensability_score
0.303

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Hpse2
Phenotype
growth/size/body region phenotype; homeostasis/metabolism phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); digestive/alimentary phenotype; renal/urinary system phenotype;

Gene ontology

Biological process
glycosaminoglycan catabolic process;biological_process;positive regulation of cell population proliferation;extracellular matrix organization
Cellular component
plasma membrane;extracellular matrix
Molecular function
heparanase activity;heparan sulfate proteoglycan binding